Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12
AI will also play a commercial role in helping engage payers by demonstrating that certain therapeutic outcomes can help prevent type 2 diabetes, reduce cardiovascular risks, and save on overall health costs
The turning point came around 2015, when higher-dose liraglutide, under the brand name Saxenda, was approved for obesity, confirming the weight loss effect wasnt just a side effect, but a primary therapeutic action. GLP-1s worked differently from earlier diet drugs
For chronic conditions like type 2 diabetes, heart disease, or kidney decline, Ozempic is often a long-term or even lifelong treatment
Mining the human gut microbiota for immunomodulatory organisms
In the last two years, hundreds of businesses have cropped up to meet the surge in demand for the obesity and diabetes medications known as GLP-1s
Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
